Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48
Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.
Filings · News reference
Avalo Therapeutics Files Prospectus For Offering Up To 128,189 Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1534120/000110465926087573/tm2620167-5_424b3.htm
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share